Entrada Therapeutics announced on June 3, 2025, the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, having served as Executive Partner at Sofinnova Investments since August 2024.
Prior to her current role, Dr. Radhakrishnan was Group Senior Vice President and Chief Medical Officer at Biogen from January 2020 to March 2024, and held leadership roles at Sanofi, Bioverativ, Bristol Myers Squibb, UnitedHealth Group, and Cephalon. Her expertise includes product development and commercialization across multiple therapeutic areas.
Entrada's CEO, Dipal Doshi, emphasized that Dr. Radhakrishnan's experience will be invaluable as the company advances its Duchenne muscular dystrophy franchise into multiple patient-focused clinical trials throughout the year. Dr. Radhakrishnan expressed honor in joining the Board, citing the promising Phase 1 safety and target engagement data for Entrada's Duchenne therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.